RxDoctor Payments Data

Steven Pascal, MD

Ophthalmology · Oakland, CANPI 1336177245

Payments from drug & device makers

$5,220in general payments, 2019–2025

Across 241 payments — averaging $21.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alcon$856
  • Oyster Point Pharma, Inc.$408
  • Sun Pharmaceutical Industries Inc.$339
  • Novartis$326
  • Sight Sciences, Inc.$277
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$5,12998%
  • Gifts$391%
  • Entertainment$521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,220 in reported general payments places this provider in the 75th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$660,432
Medicare patients
1,314
Services billed
4,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost57$31,207
XiidraLifitegrast11$16,729
MieboPerfluorohexyloctane/Pf19$16,351
CequaCyclosporine25$15,737
Cyclosporine40$14,715
RestasisCyclosporine15$10,727
VevyeCyclosporine12$10,358
SimbrinzaBrinzolamide/Brimonidine Tart33$9,487
Alphagan PBrimonidine Tartrate16$9,475
CombiganBrimonidine Tartrate/Timolol17$8,198
RhopressaNetarsudil Mesylate18$7,668
VyzultaLatanoprostene Bunod14$7,597
Brimonidine Tartrate116$7,441
Prednisolone Acetate135$5,891
RocklatanNetarsudil Mesylat/Latanoprost11$3,703

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$1,110$59,607105 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$245$40,67744 claims
Sun Pharmaceutical Industries Inc.Cequa$339$15,73725 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$47$11,37029 claims
Harrow Eye, LLCVevye$136$10,35812 claims
AlconSimbrinza$856$9,48733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Oakland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →